Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fosaprepitant Dimeglumine

FDA-approved product (powder, intravenous), marketed as Emend, Focinvez, Fosaprepitant Dimeglumine and 1 more.

Registered studies
21
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Fosaprepitant Dimeglumine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chemotherapy-induced nausea and vomiting
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiemetics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

21registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fosaprepitant Dimeglumine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fosaprepitant Dimeglumine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting

    NCT07692451 · start 2026-07-15

    Registered record
    Registry ID
    NCT07692451
    Conditions
    Nausea and Vomiting Induced by Antibody-drug Conjugates (ADCs)
    Interventions
    Fosrolapitant and Palonosetron for injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-15
    Completion
    2027-09-30
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting Induced by Antibody-drug Conjugates (ADCs)
    InterventionFosrolapitant and Palonosetron for injection
    PhasePhase 2
    Registry statusNot yet recruiting

  • To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

    NCT07081256 · start 2025-01-03

    Registered record
    Registry ID
    NCT07081256
    Conditions
    Chemotherapy-Induced Nausea and Vomiting
    Interventions
    QLM2010 for injection；dexamethasone; fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2025-01-03
    Completion
    2025-10-15
    Enrolment
    665

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting
    InterventionQLM2010 for injection；dexamethasone; fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

    NCT05509634 · start 2022-09-21

    Registered record
    Registry ID
    NCT05509634
    Conditions
    Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
    Interventions
    HR20013 for injection；dexamethasone; fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-09-21
    Completion
    2023-08-30
    Enrolment
    754

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
    InterventionHR20013 for injection；dexamethasone; fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.

    NCT05755659 · start 2022-07-15

    Registered record
    Registry ID
    NCT05755659
    Conditions
    Neoplasms
    Interventions
    Fosaprepitant Dimeglumine for Injection
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-07-15
    Completion
    2024-12-20
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionFosaprepitant Dimeglumine for Injection
    PhaseNot applicable
    Registry statusUnknown

  • Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

    NCT04054193 · start 2019-09-09

    Registered record
    Registry ID
    NCT04054193
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Fosaprepitant Dimeglumine; 5-HT3 antagonist; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-09-09
    Completion
    2021-02-11
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionFosaprepitant Dimeglumine; 5-HT3 antagonist; Dexamethasone
    PhasePhase 4
    Registry statusCompleted

  • Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

    NCT03578081 · start 2018-11-20

    Registered record
    Registry ID
    NCT03578081
    Conditions
    Malignant Neoplasm
    Interventions
    Palonosetron Hydrochloride; Ondansetron Hydrochloride; Dexamethasone; Fosaprepitant Dimeglumine; Olanzapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-11-20
    Completion
    2023-05-01
    Enrolment
    690

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm
    InterventionPalonosetron Hydrochloride; Ondansetron Hydrochloride; Dexamethasone; Fosaprepitant Dimeglumine +2 more
    PhasePhase 3
    Registry statusCompleted

  • Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

    NCT02732015 · start 2016-10-12

    Registered record
    Registry ID
    NCT02732015
    Conditions
    Locally Advanced Sarcoma
    Interventions
    Dexamethasone; Doxorubicin; Fosaprepitant Dimeglumine; Ifosfamide; Laboratory Biomarker Analysis; Mesna; Ondansetron; Questionnaire Administration; Rolapitant Hydrochloride; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-10-12
    Completion
    2020-07-10
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Sarcoma
    InterventionDexamethasone; Doxorubicin; Fosaprepitant Dimeglumine; Ifosfamide +6 more
    PhasePhase 2
    Registry statusTerminated

  • Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

    NCT01697579 · start 2012-12-13

    Registered record
    Registry ID
    NCT01697579
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Fosaprepitant; Fosaprepitant Placebo; Ondansetron; 5-hydroxytryptamine 3 antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12-13
    Completion
    2016-11-21
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionFosaprepitant; Fosaprepitant Placebo; Ondansetron; 5-hydroxytryptamine 3 antagonist
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

    NCT01594749 · start 2012-09-24

    Registered record
    Registry ID
    NCT01594749
    Conditions
    Chemotherapy-Induced Nausea and Vomiting (CINV)
    Interventions
    Fosaprepitant dimeglumine; Fosaprepitant Placebo; Dexamethasone; Ondansetron; Dexamethasone Placebo; Ondansetron Placebo; Rescue Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-09-24
    Completion
    2014-11-03
    Enrolment
    1,015

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting (CINV)
    InterventionFosaprepitant dimeglumine; Fosaprepitant Placebo; Dexamethasone; Ondansetron +3 more
    PhasePhase 3
    Registry statusCompleted

  • Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

    NCT01649258 · start 2012-09-04

    Registered record
    Registry ID
    NCT01649258
    Conditions
    Breast Cancer; Nausea; Vomiting
    Interventions
    granisetron transdermal system; fosaprepitant dimeglumine; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-09-04
    Completion
    2017-09-30
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Nausea; Vomiting
    Interventiongranisetron transdermal system; fosaprepitant dimeglumine; laboratory biomarker analysis
    PhasePhase 1
    Registry statusTerminated

  • Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

    NCT01504711 · start 2012-06

    Registered record
    Registry ID
    NCT01504711
    Conditions
    Gastrointestinal Cancer; Nausea Post Chemotherapy
    Interventions
    fosaprepitant dimeglumine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-06
    Completion
    2020-09-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Cancer; Nausea Post Chemotherapy
    Interventionfosaprepitant dimeglumine
    PhaseNot applicable
    Registry statusCompleted

  • Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

    NCT01490060 · start 2012-05

    Registered record
    Registry ID
    NCT01490060
    Conditions
    Sarcoma; Chemotherapy-induced Nausea and Vomiting; Effects of Chemotherapy; Adverse Effects of Medical Drugs
    Interventions
    Fosaprepitant; Dexamethasone; 5HT3 receptor antagonist; Ifosfamide-based chemotherapy (AI); Doxorubicin; Mesna; Ifosfamide; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-05
    Completion
    2016-03
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma; Chemotherapy-induced Nausea and Vomiting; Effects of Chemotherapy; Adverse Effects of Medical Drugs
    InterventionFosaprepitant; Dexamethasone; 5HT3 receptor antagonist; Ifosfamide-based chemotherapy (AI) +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)

    NCT01405924 · start 2011-10-25

    Registered record
    Registry ID
    NCT01405924
    Conditions
    Nausea; Vomiting
    Interventions
    Fosaprepitant dimeglumine; 5-HT3 RA; Dexamethasone; Rescue medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-10-25
    Completion
    2013-12-06
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea; Vomiting
    InterventionFosaprepitant dimeglumine; 5-HT3 RA; Dexamethasone; Rescue medication
    PhasePhase 2
    Registry statusTerminated

  • Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

    NCT01074697 · start 2010-04

    Registered record
    Registry ID
    NCT01074697
    Conditions
    Nausea; Vomiting; Genital Neoplasms, Female
    Interventions
    Fosaprepitant dimeglumine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-04
    Completion
    2015-04
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea; Vomiting; Genital Neoplasms, Female
    InterventionFosaprepitant dimeglumine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

    NCT01111851 · start 2010-04

    Registered record
    Registry ID
    NCT01111851
    Conditions
    Chemotherapy-Induced Nausea and Vomiting (CINV)
    Interventions
    Fosaprepitant 150 mg; Aprepitant 165 mg; Aprepitant 250 mg; Dexamethasone (12-8-16-16 mg); Dexamethasone (12-8-8-16 mg); Ondansetron; MK0999
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-10
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting (CINV)
    InterventionFosaprepitant 150 mg; Aprepitant 165 mg; Aprepitant 250 mg; Dexamethasone (12-8-16-16 mg) +3 more
    PhasePhase 1
    Registry statusCompleted